Incyte Corporation — FY 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are noted separately where useful.
Business context
Incyte is a biopharmaceutical company focused on small-molecule medicines for oncology and inflammation. In November 2011, the FDA approved JAKAFI (ruxolitinib) for intermediate- or high-risk myelofibrosis, and Incyte began U.S. commercialization through its own sales organization. Novartis holds rights outside the United States for specified hematologic and oncology indications; Lilly holds worldwide rights to LY3009104 for inflammatory and autoimmune diseases.
The pipeline included ruxolitinib in Phase III for polycythemia vera; LY3009104 in Phase IIb for rheumatoid arthritis and psoriasis; and earlier-stage c-MET and IDO programs.
Financial results and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Total revenue | $94.5 million | $169.9 million |
| JAKAFI product revenue | $2.0 million | None |
| Contract revenue | $91.9 million | $168.9 million |
| Research and development expense | $178.7 million | $123.9 million |
| Selling, general and administrative expense | $58.2 million | $32.3 million |
| Operating loss | $143.2 million | Operating income of $14.0 million |
| Net loss | $186.5 million | $31.8 million |
| Net loss per share | $1.49 | $0.26 |
| Cash used in operating activities | $161.7 million | Cash provided of $97.9 million |
Fourth-quarter 2011 revenue was $28.9 million, net loss was $55.1 million, and loss per share was $0.44. FY 2011 revenue included $25.0 million in Novartis milestone payments; FY 2010 included $102.0 million in milestone payments from Novartis, Lilly and Pfizer. Contract revenue also reflected recognition over time of collaboration upfront payments.
Cash, cash equivalents and short- and long-term marketable securities totaled $277.6 million at year-end, excluding $19.0 million held in a restricted escrow for note interest. Working capital was $175.2 million, down from $341.9 million. Total assets were $329.0 million and stockholders’ deficit was $227.1 million. The filing reports $420.0 million aggregate principal debt: $400.0 million of 4.75% convertible senior notes due 2015 and $20.0 million of non-interest-bearing Pfizer notes due in 2013 and 2014. Interest expense was $43.8 million.
Cost of revenue was reported as $0.0 million for 2011: inventory costs incurred before JAKAFI approval were expensed as R&D, and inventory capitalization began after approval. Therefore, a product gross margin is not meaningfully indicated for this launch period.
Material changes versus the prior year
- Revenue fell 44%, primarily because 2010 included substantially more recognized collaboration milestones and upfront-payment revenue; 2011 added initial JAKAFI sales.
- Net loss widened to $186.5 million from $31.8 million. R&D expense rose about 44%, and SG&A rose about 80%, reflecting pipeline activity and preparation for the JAKAFI launch.
- Operating cash flow shifted from $97.9 million provided to $161.7 million used. Management attributed the decline mainly to large collaborator upfront and milestone receipts in 2010.
- Cash and marketable securities fell by $146.6 million; working capital also declined substantially.
Outlook, risks and notable items
- Management expected cash, cash equivalents and marketable securities to fund capital needs for at least the next 12 months, while acknowledging possible future financing needs and continued losses. The company did not provide specific revenue, earnings or JAKAFI sales guidance.
- JAKAFI’s commercial success depends on uptake, patient identification, reimbursement and pricing, and the ability to maintain effective sales and distribution. Its $7,000 wholesale acquisition cost for a 30-day supply increases the importance of payer coverage and patient assistance.
- Supply is outsourced, with single-source exposure in important parts of JAKAFI’s manufacturing chain; raw materials include suppliers in China. A disruption or failure to qualify additional sources could impair supply.
- Incyte reported $420.0 million principal debt and covenants restricting additional debt, liens and certain asset dispositions. Debt service and refinancing or repayment needs may constrain operating flexibility.
- Clinical and regulatory outcomes remain uncertain. Ruxolitinib’s polycythemia vera Phase III trial had an FDA special protocol assessment, which the filing cautions does not guarantee approval. Other pipeline programs face trial, safety and development risks.
- A single customer represented 84% of 2011 revenue; the filing’s concentration disclosure does not identify that customer in the cited text. Revenue recognition for JAKAFI used a sell-through method, deferring approximately $2.3 million for product shipped to specialty pharmacies but not yet dispensed to patients.
- The company reported no material legal proceedings. Ernst & Young issued an unqualified audit opinion and an unqualified opinion on internal control over financial reporting. Incyte reported effective disclosure controls and internal controls.
Investor verification points
- Track JAKAFI prescription demand, net sales, reimbursement, patient access assistance, returns and the transition from sell-through to sell-in revenue recognition.
- Verify cash burn and runway against the stated 12-month liquidity expectation, including restricted cash, operating needs and debt obligations.
- Review the identity and ongoing significance of the customer responsible for 84% of FY 2011 revenue, plus the timing and likelihood of future collaboration milestones and royalties.
- Monitor progress in qualifying backup JAKAFI API and finished-product manufacturers and the resilience of the international supply chain.
- Follow clinical results, regulatory decisions and spending commitments for the polycythemia vera, rheumatoid arthritis, psoriasis and oncology programs.